Specificity of the immune response to a modified group B meningococcal polysaccharide conjugate vaccine.
Antibodies to a modified group B meningococcal polysaccharide vaccine were examined for antigenic and functional specificities. Bactericidal determinants were investigated by using immunoaffinity columns and competitive inhibition of bactericidal activity in an in vitro killing assay. We conclude that nearly all of the vaccine-induced bactericidal activity is specific for the native polysaccharide.
Moore
Samuel
S
Department of Vaccine Research, BioVeris Corporation, 16020 Industrial Drive, Gaithersburg, MD 20877, USA. smoore@bioveris.com
Farley
Esmé K
EK
Fusco
Peter C
PC
Michon
Francis
F
D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000276:immunology*; D000918:Antibody Specificity; D000942:Antigens, Bacterial / Q000276:immunology; D051379:Mice; D009345:Neisseria meningitidis / Q000145:classification / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000276:immunology*
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate